- Home
- DKL vs IDYA Comparison
DKL vs IDYA Comparison
Compare DKL & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKL
- IDYA
- Stock Information
- Founded
- DKL 2012
- IDYA 2015
- Country
- DKL United States
- IDYA United States
- Employees
- DKL N/A
- IDYA N/A
- Industry
- DKL Natural Gas Distribution
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- DKL Energy
- IDYA Health Care
- Exchange
- DKL Nasdaq
- IDYA Nasdaq
- Market Cap
- DKL 2.4B
- IDYA 2.8B
- IPO Year
- DKL N/A
- IDYA 2019
- Fundamental
- Price
- DKL $46.17
- IDYA $32.28
- Analyst Decision
- DKL Buy
- IDYA Buy
- Analyst Count
- DKL 3
- IDYA 14
- Target Price
- DKL $47.00
- IDYA $49.58
- AVG Volume (30 Days)
- DKL 75.2K
- IDYA 1.1M
- Earning Date
- DKL 11-07-2025
- IDYA 11-04-2025
- Dividend Yield
- DKL 9.85%
- IDYA N/A
- EPS Growth
- DKL 1.28
- IDYA N/A
- EPS
- DKL 3.09
- IDYA N/A
- Revenue
- DKL $967,420,000.00
- IDYA $214,834,000.00
- Revenue This Year
- DKL $15.88
- IDYA $90.17
- Revenue Next Year
- DKL N/A
- IDYA $217.29
- P/E Ratio
- DKL $14.71
- IDYA N/A
- Revenue Growth
- DKL N/A
- IDYA 5377.66
- 52 Week Low
- DKL $34.59
- IDYA $13.45
- 52 Week High
- DKL $48.00
- IDYA $33.64
- Technical
- Relative Strength Index (RSI)
- DKL 49.98
- IDYA 63.01
- Support Level
- DKL $42.82
- IDYA $30.26
- Resistance Level
- DKL $46.41
- IDYA $32.69
- Average True Range (ATR)
- DKL 1.35
- IDYA 1.41
- MACD
- DKL 0.02
- IDYA -0.03
- Stochastic Oscillator
- DKL 50.37
- IDYA 70.52
About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.